Compare CC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | TMDX |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.2B |
| IPO Year | 2014 | 2019 |
| Metric | CC | TMDX |
|---|---|---|
| Price | $22.12 | $66.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $20.11 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $6,638,000,000.00 | $605,494,000.00 |
| Revenue This Year | $6.15 | $24.25 |
| Revenue Next Year | $5.95 | $18.75 |
| P/E Ratio | ★ N/A | $341.18 |
| Revenue Growth | 7.36 | ★ 37.13 |
| 52 Week Low | $9.13 | $60.11 |
| 52 Week High | $28.67 | $156.00 |
| Indicator | CC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.68 | 31.32 |
| Support Level | $20.47 | $60.11 |
| Resistance Level | $25.69 | $120.60 |
| Average True Range (ATR) | 1.12 | 3.81 |
| MACD | -0.26 | 1.43 |
| Stochastic Oscillator | 32.64 | 61.30 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.